{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-005023","form_type":"8-K","ticker":"PAVM","cik":"0001624326","company_name":"PAVmed Inc.","filed_at":"2026-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.669344+00:00","generated_at":"2026-05-16T04:56:14.321065+00:00","sec_items":["1.01","1.02","2.03","3.02","3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PAVmed closes $30M Series D Preferred and $15M Note, retires all convertible securities","bullets":["Gross proceeds $30M from Series D Preferred; warrants exercisable for additional $30M upon positive Medicare LCD for EsoGuard.","New $15M senior secured note with 15% interest, matures Feb 2029, to existing investor.","Used $22.3M cash + $15M note to redeem all Series C Preferred and retire convertible debt; net cash $7.7M.","Series D convertible at $6.50/share; special meeting by April 30, 2026 to seek stockholder approval for conversion.","Eliminates legacy convertible overhang; PAVmed holds 31M shares of Lucid Diagnostics (Nasdaq: LUCD)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-005023","json":"https://secwatch.observer/filing/0001493152-26-005023.json","markdown":"https://secwatch.observer/filing/0001493152-26-005023.md","text":"https://secwatch.observer/filing/0001493152-26-005023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1624326/000149315226005023/0001493152-26-005023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1624326/000149315226005023/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:56:14.321065+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"071d9686d16df454fd39be68472705bf433d7174","claim":"PAVmed Inc. amended Amended and Restated 2022 Note (the \"2026 Note\") with the Holder valued at $15 million principal amount (effective 2026-02-03).","evidence_excerpt":"Concurrently with the Offering, the Company redeemed all 16,962 shares of Series C Preferred Stock outstanding and refinanced all $8,414,890 in principal and interest of its Senior Secured Convertible Note issued in September (the “ 2022 Note ”), in consideration of a cash payment to the holder thereof (the “ Holder ”) of approximately $22,346,241 (which was made using proceeds from the sale of the Series D Preferred Stock), and the issuance to the Holder of an amended and restated 2022 Note (the “ 2026 Note ”) with a principal amount of $15 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315226005023/0001493152-26-005023-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"the Holder"},{"label":"Value","value":"$15 million principal amount"},{"label":"Effective","value":"2026-02-03"}],"fact_type":"material_agreement"},{"claim_id":"89bed556382d8c3ab5a8823090d88f2465387619","claim":"PAVmed Inc. entered into Subscription Agreements with certain accredited investors valued at $30 million aggregate purchase price (effective 2026-02-03).","evidence_excerpt":"On February 3, 2026, PAVmed Inc. (the “ Company ”) entered into subscription agreements (the “ Subscription Agreements ”) with certain accredited investors (the “ Investors ”) and, pursuant to and concurrently with the execution of the Subscription Agreements, sold to the Investors, for an aggregate purchase price of $30 million, (i) 30,000 shares of the Company’s newly designated Series D Convertible Preferred Stock, par value $0.001 per share (the “ Series D Preferred Stock ”), and (ii) warrants (the “ Warrant ”) to purchase an additional 30,000 shares of Series D Preferred Stock, with each investor receiving 100 shares of Series D Preferred Stock and a warrant to purchase 100 shares of Series D Preferred Stock for each $100,000 of its investment (the “ Offering ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315226005023/0001493152-26-005023-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"$30 million aggregate purchase price"},{"label":"Effective","value":"2026-02-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}